120041-08-9

Usage

Uses

Used in Pharmaceutical Industry:
GADOTERIDOL RELATED COMPOUND A (50 MG) (10-(2-HYDROXYPROPYL)-1,4,7,10-TETRAAZACYCLODODE-CANE-1,4,7-TRIACETIC ACID) is used as an impurity in the synthesis of Gadoteridol for its application as an MRI contrast chelating agent. The presence of GADOTERIDOL RELATED COMPOUND A (50 MG) (10-(2-HYDROXYPROPYL)-1,4,7,10-TETRAAZACYCLODODE-CANE-1,4,7-TRIACETIC ACID) in the synthesis process is crucial for the development of Gadoteridol, which is employed to improve the contrast and clarity of MRI images, allowing for more accurate diagnosis and treatment planning in various medical conditions.
Used in Medical Diagnostics:
In the field of medical diagnostics, GADOTERIDOL RELATED COMPOUND A (50 MG) (10-(2-HYDROXYPROPYL)-1,4,7,10-TETRAAZACYCLODODE-CANE-1,4,7-TRIACETIC ACID) contributes to the enhancement of MRI imaging by being a part of the Gadoteridol synthesis. Gadoteridol, as an MRI contrast agent, is particularly useful in visualizing soft tissues, blood vessels, and organs, facilitating the detection and monitoring of various pathologies, such as tumors, inflammation, and vascular disorders.
Used in Research and Development:
GADOTERIDOL RELATED COMPOUND A (50 MG) (10-(2-HYDROXYPROPYL)-1,4,7,10-TETRAAZACYCLODODE-CANE-1,4,7-TRIACETIC ACID) also plays a role in research and development within the pharmaceutical and medical industries. Its presence in the synthesis of Gadoteridol may be investigated for potential improvements in the production process, optimization of the compound's properties, and exploration of new applications in diagnostic imaging and related fields.

Upstream product

• 114873-37-9 1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid 
• 75-56-9 methyloxirane 

Relevant academic research and scientific papers

METHOD FOR MANUFACTURING CALTERIDOL

It is disclosed a method for preparing calteridol used as MRI contrast agents. It provides a method for preparing calteridol comprising: obtaining teridol represented by the following Formula 2 by reacting gadoteridol represented by the following Formula 1 with decomplexing agent; and obtaining calteridol represented by the following Formula 3 by reacting calcium ion with teridol represented by following Formula 2.

NOVEL PROCESS FOR THE PREPARATION OF MACROCYCLIC CHELANT 2,2',2''-(10-(2-HYDROXYPROPYL)-1,4,7,10-TETRA AZACYCLODODECANE-1,4,7-TRIYL) TRIACETIC ACID AND IT'S COMPLEXES WITH PARAMAGNETIC METAL IONS

The present invention relates to an improved process for the preparation of macrocyclic chelant 2,2',2''-(10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) triacetic acid of formula (1). The present invention further relates to the process for the preparation of metal complexes of macrocyclic chelant 2,2',2''-(10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) triacetic acid of formula (1) with purity greater than 99.0% by HPLC. The present invention also relates to an improved process for the preparation of gadolinium complex of formula (1a) with macrocyclic chelant 2,2',2''-(10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) triacetic acid of formula (1). The present invention further relates to a novel process for the preparation of calcium complex of formula (1b) with macrocyclic chelant 2,2',2''-(10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) triacetic acid of formula (1).

Hydrolysis method of tert-butyl ester used in gadolinium contrast agent

The invention provides a hydrolysis method of tert-butyl ester used in a gadolinium contrast agent. The hydrolysis method comprises the following step: hydrolyzing the tert-butyl ester by using a catalyst. The preparation method of the catalyst comprises the following steps: performing a reaction on zirconium dioxide and titanium tetrachloride in the presence of sulfuric acid and water at 60-90 DEG C until a solid is dissolved, adding silicon dioxide for reaction for 1-5 hours, filtering a reaction product and collecting the solid, and washing and roasting the solid. No acid or other substances difficult to remove are introduced into the hydrolysis method, so that the hydrolysis efficiency is high, and the purity of the obtained product is high.

Preparation method and application for gadolinium ion type contrast agent intermediate

The invention provides a preparation method and an application for a gadolinium ion type contrast agent intermediate. The preparation method comprises the following steps: allowing a substance as shown in a general formula (II) which is described in the specification to react with a substance as shown in a general formula (III) which is described in the specification or a substance as shown in a general formula (IV) which is described in the specification in the presence of an alkaline catalyst so as to generate the gadolinium ion type contrast agent intermediate with a structure as shown in ageneral formula (I) or a general formula (V) which are described in the specification. In the general formulas as described in the specification, R represents a group selected from the group consisting of C1-C5 alkyl groups, benzyl groups and benzyl derivatives; R1 represents -H or -CH2OH; and R2 represents -CH3 or -OH. The above-mentioned preparation method used to prepare the gadolinium ion type contrast agent intermediate with a structure as shown in the general formula (I) which is described in the specification has the advantages of simple reaction, fewer steps and controllable reaction,and can reach a yield of 99% or above; and a product obtained by using the preparation method provided by the invention has a purity of more than 99.5%.

Graphene Oxide Cellular Delivery of Hydrophilic Small Molecules

Unmodified graphene oxide conjugated with hydrophilic small molecules for cellular delivery.

Polyazacycloalkane compounds

The present invention relates to tribenzylcyclen compounds of formula I STR1 (where R is hydrogen, or a C1-12 alkyl group optionally substituted by hydroxy, alkoxy or aryl groups or R is an amphiphilic aralkyl group comprising a N, S, O or P in

Aminopolycarboxylic acids and derivatives thereof

There are provided chelating agents particularly useful for the preparation of diagnostic and therapeutic agents for magnetic resonance imaging, scintigraphy, ultrasound imaging, radiotherapy and heavy metal detoxification, said agents being compounds of formula I wherein n and m are 2, 3 or 4; and A, X, R1 and Z are as defined in the specification.

Process for the production of N-β-hydroxyalkyl-tri-N-carboxyalkyl-1,4,7,10-tetraazacyclododecane and N-β-hydroxyalkyl-tri-N-carboxyalkyl-1,4,8,11-tetraazacyclotetradecane derivatives and their metal complexes

A process for the production of N-β-hydroxyalkyl-tri-N-carboxyalkyl-1,4,7,10-tetraazacyclododecane and N-β-hydroxyalkyl-tri-N-carboxyalkyl-1,4,8,11-tetraazacyclotetradecane derivatives and their metal complexes is described.

Aminopolycarboxylic acids and derivatives thereof

There are provided chelating agents particularly useful for the preparations of diagnostic and therapeutic agents for magnetic resonance imaging, scintigraphy, ultrasound imaging, radiotherapy and heavy metal detoxification, said agents being compounds of formula X--CHR1 --NZ--(CHR1)n --A--(CHR1)m --NZ--CHR1 --X wherein (each of the groups Z is a group --CHR1 X or the groups Z together are a group --(CHR1)q --A'--(CHR1)r --, where A' is an oxygen or sulphur atom or a group --N--Y; A is a group --N--Y or A--(CHR1)m -- represents a carbon-nitrogen bond or, when the groups Z together are a group --(CHR1)q --A'--(CHR1)r --, A may also represent an oxygen or sulphur atom; each Y, which may be the same or different, is a group --(CHR1)p --N(CHR1 X)2 or a group --CHR1 X; each X, which may be the same or different, is a carboxyl group or a derivative thereof or a group R1 ; each R1, which may be the same or different, is a hydrogen atom, a hydroxyalkyl group or an optionally hydroxylated alkoxy or alkoxyalkyl group; n, m, p, q and r are each 2, 3 or 4; with the provisos that at least two nitrogens carry a --CHR1 X moiety wherein X is a carboxyl group or a derivative thereof, that each --CHR1 X moiety is other than a methyl group, and that unless A' is oxygen or sulphur or A is N--(CHR1)p --N(CHR1 X)2 at least one R1 is other than hydrogen) and salts thereof.